A61P 17 - Drugs for dermatological disorders

Patents for A61P 17 - Drugs for dermatological disorders (106,455)
10/2002
10/17/2002	WO2002062301A3 Method and composition for rejuvinating cells, tissues, organs, hair and nails
10/17/2002	WO2002059114A9 Lfa-1 antagonist compounds
10/17/2002	WO2002056897A3 Pharmaceutical for stimulating the regeneration of tissues
10/17/2002	WO2002042292A3 Indol derivative and their use as inhibitors of p38 kinase
10/17/2002	WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002	WO2002038607A3 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
10/17/2002	WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002	WO2002029061A3 G-protein coupled receptors
10/17/2002	WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002	WO2002007772A3 Improved oral dosage formulations
10/17/2002	WO2002002133A3 Peptide composition for treatment of periodontal diseases and prevention of skin aging
10/17/2002	WO2001098344A3 Angiogenesis-modulating compositions and uses
10/17/2002	WO2001098323A3 G-protein coupled receptors
10/17/2002	WO2001091736A3 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
10/17/2002	WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002	US20020152481 Genetic engineering; qualitative analysis
10/17/2002	US20020151695 Transforming growth factor-beta-related molecules and uses thereof
10/17/2002	US20020151680 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
10/17/2002	US20020151599 Formulations having an antiviral action
10/17/2002	US20020151591 4-oxo-1,4-tetrahydro-1,5- naphthyridine-3-carboxamide derivative useful in treatment of disorders associated with cognition impairment including, Alzheimer's, vascular dementia, Parkinson's disease etc
10/17/2002	US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002	US20020151577 Antiparasitic composition for the treatment and protection of pets
10/17/2002	US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors
10/17/2002	US20020151573 Anticancer agents
10/17/2002	US20020151572 Nitric oxide synthase (NOS); alone or in combination with another active agent for the treatment of psoriasis, an antiinflammatory, an analgesic, a cognition enhancer or sleep disorder treatment
10/17/2002	US20020151558 Triazolo compounds as MMP inhibitors
10/17/2002	US20020151553 Such as 4-(4-chlorophenyl)1-(3-(5-cyano-5H-dibenzo(a,d) cycloheptene-5-yl)propyl)piperidin-4-ol for treatment of diseases associated with aberrant leukocyte recruitment and/or activation
10/17/2002	US20020151547 Substituted phenyl-piperidine methanone compounds
10/17/2002	US20020151528 Use of 2alpha-methyl-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 to increase bone strength
10/17/2002	US20020151511 Antisense oligonucleotide modulation of human MDM2 expression
10/17/2002	US20020151501 Compounds having growth hormone releasing activity
10/17/2002	US20020151497 Inhibitors comprise sequences derived from specific regions of the Lyn-kinase
10/17/2002	US20020151487 Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
10/17/2002	US20020151483 C3b/C4b complement receptor-like molecules and uses thereof
10/17/2002	US20020151480 Identifying a compound to treat a cardiovascular disease, e.g., atherosclerosis, characterized by aberrant 10218 nucleic acid activity or expression; detecting the presence of a nucleic acid in the sample that hybridizes to the probe
10/17/2002	US20020151475 Compounds and methods for modulating cell adhesion
10/17/2002	US20020151460 Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
10/17/2002	US20020151022 Kinase capable of site-specific phosphorylation of IkappaBalpha
10/17/2002	US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002	US20020150986 Extracellular matrix signalling molecules
10/17/2002	US20020150888 Methods of screening for modulators of HIV infection
10/17/2002	US20020150638 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/17/2002	US20020150601 Topical applying
10/17/2002	US20020150600 Conjugate, its preparation and use
10/17/2002	US20020150572 Methods and compositions for the treatment of psoriasis
10/17/2002	US20020150559 Binding of human antigens
10/17/2002	US20020150547 Blend of plant extracts and biopolymer
10/17/2002	DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections
10/17/2002	DE10117184A1 Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen Substituted imidazol [1,2-a] pyridin-3-yl-amide, and amine compounds of
10/17/2002	CA2762966A1 Hsa-free formulations of interferon-beta
10/17/2002	CA2719162A1 Methods of treating acne
10/17/2002	CA2699611A1 Desaturase genes and uses thereof
10/17/2002	CA2698579A1 Desaturase genes and uses thereof
10/17/2002	CA2443405A1 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002	CA2443378A1 Methods of screening and using inhibitors of angiogenesis
10/17/2002	CA2443099A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002	CA2443085A1 Somatostatin agonists
10/17/2002	CA2443057A1 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002	CA2442996A1 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002	CA2442986A1 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments
10/17/2002	CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002	CA2442382A1 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/17/2002	CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/16/2002	EP1249239A1 Antipruritic agents for external use
10/16/2002	EP1249238A2 Topical pharmaceutical composition comprising betanechol
10/16/2002	EP1249237A1 Skin external agents and drugs
10/16/2002	EP1248847A1 Irak-4: compositions and methods of use
10/16/2002	EP1248842A1 2871 receptor, a g-protein coupled receptor and methods of use thereof
10/16/2002	EP1248835A2 Genetically modified fibroblast cell
10/16/2002	EP1248830A1 Antimicrobial compositions
10/16/2002	EP1248801A1 Human polynucleotides, polypeptides, and antibodies
10/16/2002	EP1248794A1 Antisense modulation of smad7 expression
10/16/2002	EP1248787A2 Novel subtituted pyrazolo[4, 3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
10/16/2002	EP1248785A1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
10/16/2002	EP1248782A1 Anticancer compound and enantiomer separation method useful for synthesizing said compound
10/16/2002	EP1248781A1 Pyrazole cyclic amp-specific pde inhibitors
10/16/2002	EP1248774A2 Polyhydroxystilbenes and stilbene oxides as antipsoriatic agents and protein kinase inhibitors
10/16/2002	EP1248630A1 Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method
10/16/2002	EP1248627A2 Use of dehydroepiandrosterone, its precursors and derivatives, by oral administration, as hydrating agents with direct action
10/16/2002	EP1248623A2 Treatment of diabetic ulcers
10/16/2002	EP1248615A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
10/16/2002	EP1248610A2 Use of at least a fatty ester for preparing a composition designed to inhibit 5-alpha-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive
10/16/2002	EP1248608A2 Substances for use in treating psoriasis
10/16/2002	EP1248593A1 Treatment of uv induced immunosuppression
10/16/2002	EP1248552A1 Pp14 fusion proteins and methods for making and using the same
10/16/2002	EP1210094A4 Herbal compositions and uses for the treatment of allergic reactions
10/16/2002	EP0991653B1 Novel compounds
10/16/2002	EP0941108B1 Wound healing and treatment of fibrosis
10/16/2002	EP0927161B1 Substituted cyclic amine metalloprotease inhibitors
10/16/2002	EP0910354B1 Antioxidant compounds
10/16/2002	EP0802731B1 Prophylactic treatment of allergic contact dermatitis
10/16/2002	CN1374966A 嘌呤衍生物 Purine derivatives
10/16/2002	CN1374960A Novel integrain receptor antagonists
10/16/2002	CN1374955A Oxa-and thiazole derivatives useful as antidiabetic and antibesity agents
10/16/2002	CN1374952A Benzimidazolone derivatives and their use as phosphodiesterase inhibibors
10/16/2002	CN1374950A Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
10/16/2002	CN1374835A Method for the production of polyvinylpyrrolidone-iodine in an aqueous solution
10/16/2002	CN1374309A Application of cinidium general coumarin as psoriasis treating medicine
10/16/2002	CN1374102A Dermatitis treating ointment and its prepn
10/16/2002	CN1374100A Psoriasis treating capsule and its prepn

1 ... 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 ... 1065